BioXcel Therapeutics. has been granted a patent for methods of administering high doses of dexmedetomidine to treat agitation in humans, particularly in neurodegenerative and neuropsychiatric conditions. The method involves an oromucosal formulation with specific dosing guidelines to minimize sedation. GlobalData’s report on BioXcel Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on BioXcel Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. BioXcel Therapeutics's grant share as of June 2024 was 19%. Grant share is based on the ratio of number of grants to total number of patents.
Methods for treating agitation with dexmedetomidine without sedation
The granted patent US11998529B2 outlines a method for treating agitation in human subjects using an oromucosal formulation of dexmedetomidine. The treatment protocol involves administering an initial dose of dexmedetomidine, which can range from 60 mcg to 180 mcg, followed by a second dose after a minimum interval of two hours. The second dose is specified to be between 40 mcg and 90 mcg, contingent upon the persistence of agitation and the subject's corrected QT interval (QTcF), which must be less than 470 msec. The claims further detail specific dosing combinations and conditions under which the second dose may be administered, including considerations for blood pressure and heart rate.
Additionally, the patent specifies that the initial and second doses can be tailored based on the subject's QTcF, with particular emphasis on maintaining a QTcF of less than 450 msec for certain claims. The method is designed to ensure safety and efficacy in managing agitation, with specific parameters for patient monitoring, including changes in PEC scores and vital signs. The claims provide a comprehensive framework for the administration of dexmedetomidine, highlighting its potential therapeutic application in clinical settings for patients experiencing agitation.
To know more about GlobalData’s detailed insights on BioXcel Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
